Erythromycin IR Pellets are pharmaceutical-grade multiparticulate pellets containing Erythromycin and designed for immediate-release oral dosage-form development. The pellet format provides a convenient platform for capsule filling and other multiparticulate formulation applications.
Erythromycin is identified by CAS Number 114-07-8, with molecular formula C₃₇H₆₇NO₁₃ and molecular weight 733.93 g/mol. These identity details are supported by NIST and pharmaceutical reference-standard data.
Erythromycin is available in several pharmaceutical formulation formats, including pellet-based systems. Published research has specifically investigated the gastrointestinal behavior of multiparticulate Erythromycin pellets, demonstrating the established use of pellets as a formulation platform.
Commercial Indian pellet listings also identify Erythromycin IR Pellets with a reported 68% loading. This is a market reference and should not be entered as the SDP finished-pellet strength unless your actual SDP specification confirms 68%.
Erythromycin Immediate-Release Pellets are designed to provide rapid release characteristics appropriate to the finished formulation. The final performance depends on pellet composition, active loading, pellet size, excipient system and manufacturing process.
The pellet format can provide advantages for multiparticulate formulation development because individual pellets can be manufactured with controlled particle characteristics and subsequently incorporated into suitable oral dosage forms.
Erythromycin pellet systems may also be differentiated by their release characteristics. For example, commercially available Erythromycin delayed-release capsules use enteric-coated Erythromycin base pellets, demonstrating that the pellet core and coating system can be engineered for different release objectives.
For an IR pellet page, however, the SEO and technical positioning should remain focused on immediate-release Erythromycin Pellets rather than enteric-coated or delayed-release terminology.
Erythromycin IR Pellets can be considered for:
Erythromycin IR Pellets may be manufactured using suitable pelletization, layering or other multiparticulate processing technologies.
Important product parameters can include:
The final acceptance criteria should be established through the applicable finished-pellet product specification.
Erythromycin IR Pellets may be evaluated for:
USP has current monograph material for Erythromycin dosage forms and related analytical procedures, including HPLC-based assay and organic-impurity testing for Erythromycin delayed-release tablets.
Erythromycin Pharmaceutical Pellets provide a multiparticulate platform for formulation developers requiring controlled pellet characteristics and convenient incorporation into oral dosage forms.
The Erythromycin IR pellet format can be used where an immediate-release profile is required. Active loading, pellet dimensions, moisture limits and dissolution criteria should be established according to the individual product specification.
Erythromycin IR Pellets can be supplied in suitable pharmaceutical bulk packaging according to the applicable product specification. Active loading, pellet size, packaging configuration and analytical requirements should be confirmed before commercial supply.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |